Premium
Deletion of the 5′‐ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia‐positive chronic myeloid leukaemia patients
Author(s) -
Herens C.,
Tassin F.,
Lemaire V.,
Beguin Y.,
Collard E.,
Lampertz S.,
Croisiau C.,
Lecomte M.,
De Prijk B.,
Longrée L.,
Koulischer L.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02142.x
Subject(s) - abl , fluorescence in situ hybridization , chronic myeloid leukaemia , cytogenetics , philadelphia chromosome , medicine , in situ hybridization , myeloid , microbiology and biotechnology , cancer research , immunology , pathology , biology , chromosomal translocation , genetics , chromosome , gene , tyrosine kinase , messenger rna , receptor
Inclusion of the BCR–ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph+) chronic myeloid leukaemia patients characterized by a 5′‐ ABL deletion. This anomaly was observed in 5/51 cases (9·8%). Cytological and clinical data suggest that the 5′‐ ABL deletion may be associated with dysplastic features of polymorphonuclear cells and metamyelocytes and a short chronic phase duration.